when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

TROP-2 · news · pharmadog

← back to TROP-2

News · TROP-2

96 stories

May 13, 26How Reimagined Research Endeavors Intersect With Dignified End-of-Life Care: With D. Ross Camidge, MD, PhD; and Charles D. Blanke, MD, FACP, FASCOonclive

May 13, 26BRUIN CLL-321 Trial Impact and Treatment Selectiononclive

May 13, 26Biomarker-Driven Treatment Decisions and Managing Progression After Frontline Immunotherapyonclive

May 12, 26Dr McCann on the FDA Approval of Vepdegestrant for ESR1-Mutated, ER+ Advanced Breast Canceronclive

May 12, 26Honesty and Humor Provide Hope in Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Annie Bondonclive

May 12, 26Dr Postow on an Ideal Post-ICI Monitoring Framework in Melanomaonclive

May 12, 26Dr Postow on the Timing of Delayed or Re-Emergent irAEs in Melanomaonclive

May 12, 26Temple Health’s Fox Chase Cancer Center and Labcorp Collaborate to Test Ultra-Sensitive Blood-Based Assay for Early-Stage Lung Cancer Recurrence Riskonclive

May 12, 26GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026onclive

May 12, 26Unmet Needs in Endometrial Canceronclive

May 12, 26EGFR-Mutated NSCLC: Mechanism and Clinical Role of TROP2-Directed ADCsonclive

May 12, 26Future Directions in Relapsed and Refractory Multiple Myelomaonclive

May 12, 26Dr Parikh on the Feasibility and Importance of Immunotherapy Trials in Anal Canceronclive

May 12, 26Sequencing Strategies After Progression in Multiple Myelomaonclive

May 12, 26EGFR-Mutated NSCLC: Targeting MET-Driven Resistance in Second-Line Therapyonclive

May 12, 26Sequencing ADCs in Endometrial Canceronclive

May 12, 26Second Clinical Scenario - Progressive Disease Despite Hematocrit Controlonclive

May 11, 26Dr Silbermann on Clinical Trial Design Considerations in Multiple Myelomaonclive

May 11, 26MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumorsonclive

May 11, 26Dr Randall on the Rationale for Investigating CSF-1R Inhibition in TGCTonclive

May 11, 26Renal Cell Carcinoma: Real-World Factors in First-Line Treatment Selectiononclive

May 11, 26Expanding ctDNA Applications to RCC and Germ Cell Tumorsonclive

May 11, 26RAPNO Criteria and MRI Assessment in PLGG: Recommendations vs. Real-World Practiceonclive

May 11, 26ctDNA in Metastatic Urothelial Carcinomaonclive

May 11, 26Institutional Perspectives on Treatment Thresholds in PLGGonclive

May 11, 26Renal Cell Carcinoma: Practical Treatment Selection Across Risk Groupsonclive

May 10, 26Five Under 5: Top Oncology Videos for the Week of 5/3onclive

May 9, 26The OncFive: Top Oncology Articles for the Week of 5/3onclive

May 8, 26Dr Randall on Long-Term Responses and Functional Benefits With Pimicotinib in TGCTonclive

May 8, 26Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast Canceronclive

← prevpage 2 of 4next →